NVO Stock — Price, Charts & Analysis

Novo Nordisk A/S (NVO) has a trailing P/E of 11.42x and a forward P/E of 13.43x. This places NVO in a lower earnings multiple territory based on the valuation data currently available on Worldtickers.

NVO trades with 11.42x earnings on Worldtickers. Use valuation together with growth, balance sheet strength, and risk before deciding whether NVO looks overvalued or undervalued.

NVO's P/E of 11.42x should be judged against Healthcare peers, growth rate, margins, and balance sheet quality. A lower P/E may indicate value, while a higher P/E often means investors expect stronger future growth.

NVO's trailing EPS is $4.04 and forward EPS is $3.43. Reported earnings growth is -20.60%, which helps show current profit momentum.

EPS, or earnings per share, shows how much profit Novo Nordisk A/S generated for each share. NVO's trailing EPS is $4.04, and investors usually prefer EPS that is positive and growing over time.

Novo Nordisk A/S has a market cap of $204.03B, making NVO a large-cap stock based on the current market value shown on Worldtickers.

NVO's latest stock price on Worldtickers is $46.14. The latest move is -$0.34 or -0.73%. Use the live quote, chart, volume, and 52-week range to judge the current trading context.

NVO's quote includes a latest price of $46.14. The market open is $46.89. Previous close is $46.48. The intraday range is $46.11 to $46.90.

NVO is down in the latest quote, with a move of -$0.34 or -0.73%. To understand the reason, compare this move with news, earnings updates, analyst changes, sector performance, and market-wide direction.

NVO generated $329.43B in trailing revenue. Revenue growth is 2.10%, which helps show whether demand is expanding or slowing.

NVO's revenue growth is 2.10%, which is a positive demand signal in the latest available data. Investors usually compare revenue growth with margin trends and valuation to judge whether growth is profitable.

Yes, NVO shows positive profitability metrics in the latest data available on Worldtickers. Net income to common shareholders is $116.44B.

Gross margin is 81.99%. Margins show how efficiently Novo Nordisk A/S turns revenue into profit.

Novo Nordisk A/S carries $140.13B and holds $44.98B in cash.

NVO holds $44.98B on its balance sheet.

NVO's book value per share is $7.01.

Yes, Novo Nordisk A/S pays a dividend of $1.80 per share annually. The dividend yield is 387.00%. The payout ratio is 44.46%.

NVO's dividend yield is 387.00%. Its payout ratio is 44.46%, which helps judge dividend sustainability. Dividend investors usually prefer a reasonable yield, consistent cash flow, and a payout ratio that leaves room for reinvestment.

Worldtickers does not currently show a confirmed next ex-dividend date for NVO. The page does show dividend rate and yield when available, and investors should confirm record and payment dates through Novo Nordisk A/S's investor relations materials.

NVO's five-year average dividend yield is 186.00%. Use this alongside current yield, payout ratio, and cash flow to understand whether today's dividend looks high or low versus recent history.

Institutions hold 9.90% of NVO shares. Insiders hold 0.00% of shares. Ownership mix helps investors understand how much of Novo Nordisk A/S is held by professional investors and company insiders.

NVO has 3.35B shares outstanding. Float shares are 3.17B. Share count affects market cap, EPS, ownership percentages, and the impact of buybacks or dilution.

Insider activity can be useful context for NVO, especially when multiple executives buy shares with their own money. Insider selling is harder to interpret because executives may sell for taxes, diversification, or planned compensation reasons.

Forward EPS for NVO is $3.43. Earnings growth is -20.60%. Revenue growth is 2.10%. For earnings, investors usually watch EPS, revenue, margins, guidance, and management commentary.

NVO's trailing EPS is $4.04. Forward EPS is $3.43. Use the earnings section on the page to compare reported results, estimates, and trend changes when those datasets are available.

NVO is in the Healthcare sector. Its earnings multiple is 11.42x. Its latest displayed growth metric is 2.10%. Compare these figures with sector peers before deciding whether Novo Nordisk A/S is stronger or weaker than average.

NVO trades at $46.14. The stock trades at 11.42x earnings. Whether to invest depends on your risk tolerance, time horizon, diversification, and view of Novo Nordisk A/S's fundamentals.

NVO risks include company execution, valuation, competition in Healthcare, interest rates, and broad market volatility. Beta is 0.35, which helps estimate market sensitivity. No single stock should be evaluated without portfolio context.

NVO should be compared with companies in Drug Manufacturers - General. Its earnings multiple is 11.42x. Useful comparison points include revenue growth, margins, debt, cash flow, valuation, analyst targets, and price momentum.

Novo Nordisk A/S (NVO) operates in Healthcare, specifically Drug Manufacturers - General. Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides

NVO trades on NYSE. Exchange context matters because trading hours, liquidity, currency, and settlement rules can differ across markets.

NVO stock is priced in USD on Worldtickers. Currency matters for international investors because exchange-rate moves can affect local-currency returns.

Novo Nordisk A/S's official website listed on Worldtickers is www.novonordisk.com/investors/default.asp. Investor relations pages are useful for earnings releases, annual reports, filings, and shareholder presentations.

Novo Nordisk A/S employs about 66.7K people based on the latest company profile data available on Worldtickers. Workforce size helps investors understand company scale and operating complexity.

Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark. Headquarters location can matter for currency, regulation, tax, labor market, and regional economic exposure.

NVO is in the Healthcare sector and the Drug Manufacturers - General industry. Sector context helps investors compare valuation, growth, margins, and risk against similar companies.

NVO has traded between $35.12 and $64.16 over the past 52 weeks. At $46.14, it is 28.09% below the high and 31.38% above the low. The 52-week range helps gauge long-term price momentum.

NVO is between its 50-day and 200-day moving averages, which suggests a mixed trend setup. Its 50-day moving average is $46.94 and its 200-day moving average is $45.01.

NVO's RSI is 47.64. Readings below 30 are commonly viewed as oversold, above 70 as overbought, and the current reading suggests a neutral momentum setup.

NVO's latest RSI reading is 47.64, which points to neutral momentum today. Traders usually confirm RSI with volume, trend, and nearby support or resistance.

Key support for NVO is near $43.13. Key resistance is near $51.46. Breaks above resistance or below support can change the short-term technical setup.

NVO's nearest reported support level is $43.13. A clean break below support can weaken the short-term setup, while repeated bounces can show demand.

NVO's nearest reported resistance level is $51.46. A breakout above resistance can improve momentum, especially when volume confirms the move.

NVO trades about 12.4M shares daily on average. The latest displayed volume is 9.66M shares. Volume helps show liquidity and whether trading interest is unusually high or low.

NVO's MACD is -0.08, which is a negative momentum reading. MACD should be reviewed with price trend, moving averages, RSI, volume, and support or resistance levels.

NVO is between its 50-day and 200-day moving averages, which suggests a mixed trend setup. RSI is 47.64 (neutral). MACD is bearish. Nearest support is around $43.13. Resistance is around $51.46. A buy decision should also consider valuation, earnings quality, risk tolerance, and position sizing.

MA20 is $46.81 (-1.44% from price). MA50 is $46.94 (-1.71% from price). MA200 is $45.01 (2.50% from price). The moving-average stack helps separate short-term momentum from long-term trend risk.

The server report currently confirms daily moving-average levels rather than a separate EMA-only value. NVO's MA20 is $46.81. MA50 is $46.94. For EMA-specific overlays, use the live chart indicators and compare EMA direction with RSI, MACD, volume, support, and resistance.

NVO's pivot is near $46.51. Support is near $43.13. Resistance is near $51.46. Price holding above pivot can support a constructive setup, while rejection near resistance can cap momentum.

The next lower support zone for NVO is near $44.74. The next upper resistance zone is near $47.78. These levels help define risk and possible follow-through zones after a breakout or breakdown.

NVO's Bollinger range is roughly $42.75 to $50.88. Band width is near 17.35%. Price near the upper band can show stretched upside momentum, while price near the lower band can show downside pressure or a possible mean-reversion zone.

NVO's ATR-based typical daily range is about 3.08%. ATR helps size risk because wider ranges usually require wider stops or smaller position sizes.

Latest volume is 9.66M shares. Average volume is about 12.4M shares. Breakouts with rising relative volume are usually more reliable than moves on light participation.

NVO's all-time high shown on Worldtickers is $148.15. Its all-time low is $0.09. All-time levels provide long-range context, but recent fundamentals and market conditions matter more for current decisions.

NVO has a beta of 0.35, meaning it has historically been less volatile than the broad market. Beta is useful for judging how much a stock may move during broad market swings.